Skip to content
NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · MID CAP

Pacific Biosciences of California, Inc. PACB

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$160.0M
▲ 3.9% YoY
$-546.4M
$-113.9M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

It designs, develops and manufactures advanced sequencing solutions, including its HiFi long-read sequencing technology, addressing applications in human germline sequencing, plant and animal sciences, infectious disease and microbiology, and oncology. As of December 31, 2025, it had 485 full-time employees, most of whom are based in California. Its key manufacturing and service facility, which has received ISO 13485 and ISO 9001 certifications, is located in Menlo Park, California. As of December 31, 2025, it owned or held exclusive licenses to 450 issued U.S. patents and 318 issued foreign patents, along with pending applications in both. For the years ended December 31, 2025, 2024, and 2023, no customer accounted for 10% or more of its total revenue. It markets its products through a global sales force and through distribution partners in Australia, parts of Asia, Europe, the Middle East, Africa, Central America and South America.

Written from the business description in PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 25 February 2026. Every sentence was checked against that document before publication.

Growth

USD 160.0M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 160.0 · Net income -546.4
100M200M-200M-400M
2009201220152018202120242025
Compound annual growth
+7.6%
+15.2%
+5.6%
+35.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +15.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−341 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -346.2% · Net -341.5%
-100%-200%-300%
200920172025
ROE
FY2025 · ROE -213.5%
-100%-200%
200920172025
Three returns, three denominators.
Gross margin28.6%
Operating margin-346.2%
Net margin-341.5%
EBITDAUSD -540.9M

Each USD of equity lost 213 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -113.9
-100M-200M
200920172025
Net buybacks $ Dividends $
FY2009 · Dividends · · Net buybacks -303000.0
-150000-300000
2009

Total assetsUSD 784.1M
EquityUSD 5.3M
CashUSD 63.7M
Current ratio5.15×

Equity funds 1% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PACB, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.20.20.20.10.10.10.10.10.10.10.10.10.00.00.00.00.0
Operating income $B−0.6−0.5−0.3−0.3−0.2−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1◌◌
EBITDA $B−0.5−0.5−0.3−0.3−0.2−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1◌◌
Income tax $B0.00.0−0.00.0−0.1◌◌◌◌◌◌◌◌◌◌◌◌
Net income $B−0.5−0.3−0.3−0.3−0.20.0−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1−0.1−0.1
Free cash flow $B−0.1−0.2−0.3−0.3−0.10.0−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1
EPS, diluted $−1.82−1.59−1.21−1.40−0.890.17−0.55−0.76−0.87−0.83−0.42−0.94−1.26−1.69−2.03−14.10−173.03
Dividend / sh $0.000.000.000.000.000.000.000.000.000.000.000.000.00◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %−213.5−51.3−48.5−46.4−32.215.1−99.6−102.5−108.0−94.0−49.3−106.6−88.8−62.8−46.4——
Shares out B0.300.290.270.230.220.190.150.150.120.090.080.070.070.060.000.05◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 80 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: cost of revenue is not tagged before 2011. Three checks were skipped: the share count is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityLaboratory Analytical Instruments
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2009

Share this section

Download image